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a b s t r a c t
The antiarrhythmic drug amiodarone delays cardiac repolarisation through inhibition of hERG-encoded
potassium channels responsible for the rapid delayed rectifier potassium current (IKr). This study aimed
to elucidate molecular determinants of amiodarone binding to the hERG channel. Whole-cell patch-
clamp recordings were made at 37 C of ionic current (IhERG) carried by wild-type (WT) or mutant
hERG channels expressed in HEK293 cells. Alanine mutagenesis and ligand docking were used to inves-
tigate the roles of pore cavity amino-acid residues in amiodarone binding. Amiodarone inhibited WT out-
ward IhERG tails with a half-maximal inhibitory concentration (IC50) of45 nM, whilst inward IhERG tails in
a high K+ external solution ([K+]e) of 94 mM were blocked with an IC50 of 117.8 nM. Amiodarone’s inhi-
bitory action was contingent upon channel gating. Alanine-mutagenesis identified multiple residues
directly or indirectly involved in amiodarone binding. The IC50 for the S6 aromatic Y652A mutation
was increased to 20-fold that of WT IhERG, similar to the pore helical mutant S624A (22-fold WT con-
trol). The IC50 for F656A mutant IhERG was 17-fold its corresponding WT control. Computational docking
using a MthK-based hERG model differentiated residues likely to interact directly with drug and those
whose Ala mutation may affect drug block allosterically. The requirements for amiodarone block of aro-
matic residues F656 and Y652 within the hERG pore cavity are smaller than for other high affinity IhERG
inhibitors, with relative importance to amiodarone binding of the residues investigated being
S624A  Y652A > F656A > V659A > G648A > T623A.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The benzofuran-based Class III antiarrhythmic drug amiodarone
is used in the treatment of both supraventricular and ventricular
arrhythmias [1,2]. It is recommended for the pharmacological car-
dioversion of recent onset atrial fibrillation (AF) in patients with
structural heart disease, may enhance the effectiveness of direct
current cardioversion of AF and can be useful for long-term
rate-control in patients with a history of AF [3]. Intravenous
amiodarone is the most effective pharmacological approach for
managing life-threatening ventricular arrhythmias and is valuable
in the treatment of cardiac arrest [4,5]. Amiodarone’s compara-
tively favourable safety profile is likely to result from the fact that
the drug has multiple cardiac ion channel-blocking effects
(on K+, Na+ and Ca2+ channels) as well as b-adrenoceptor blocking
activity (for reviews see [1,2]).
Rapid and slow delayed rectifier K+ currents (IKr and IKs respec-
tively) are important contributors to cardiac action potential repo-
larisation [6,7]. Short term administration of amiodarone
preferentially inhibits ventricular IKr over IKs, a result replicated
in experiments on recombinant ‘‘hERG” and ‘‘KCNQ1 + KCNE1”
channels [8], for nomenclature see [9]. Amiodarone was first
http://dx.doi.org/10.1016/j.bcp.2016.05.013
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demonstrated to inhibit hERG (human-Ether-à-go-go-Related Gene)
encoded channels in 1999 [10]. hERG current (IhERG) measurements
from Xenopus oocytes showed a half-maximal inhibitory concen-
tration (IC50) of 9.8 lM, with suggested mixed channel-state
(closed, open, inactivated channel) block [10]. Similar to other
drugs, amiodarone’s IhERG blocking potency is greater when the
drug is tested on mammalian cell lines expressing hERG [11–15].
With mammalian expression systems, IhERG IC50 values for amio-
darone of between 26 and 300 nM were reported [12–14,16,17]
and its metabolite desethyl-amiodarone (DEA) has been shown
also to inhibit IhERG, with an IC50 of 160 nM [14]. It is likely, there-
fore, that IhERG/IKr blockade contributes to the acute clinical effects
of amiodarone administration and that an inhibitory action of DEA
additionally contributes to the chronic actions of the drug [14].
hERG channels are of particular pharmacological interest as
they have a high susceptibility to pharmacological blockade by
diverse cardiac and non-cardiac drugs, an action that is strongly
associated with drug-induced Long QT Syndrome (diLQTS)
[18,19]. The channel’s ability to interact with diverse drugs is
attributed to structural features of the channel that include a com-
paratively large inner cavity and the presence of aromatic amino-
acid residues (Y652 and F656) in the S6 domain that favour drug
interactions [18,19]. For example, alanine mutants of Y652 and
F656 have been shown to increase the IC50 for hERG block by the
methansulphonanilide MK-499 by 94-fold and 650-fold respec-
tively [20], and they also have a profound effect on the inhibitory
actions effects of the related drugs dofetilide and E-4031 [21].
For many (typically high affinity) drugs hERG channel inactivation
also appears to contribute to the drug-channel interaction
[13,18,19,22].
Amiodarone appears to differ from canonical IhERG inhibitors in
the extent to which channel inactivation influences blocking
potency [13]. In a direct comparison with E-4031, amiodarone’s
action was impaired less than that of E-4031 by attenuated-
inactivation mutants [13]. Moreover, the effects of a profound
blocking concentration of amiodarone (10 IC50 for wild-type
hERG) have been reported to be only partially attenuated by muta-
tion at Y652, whilst a concentration blocking WT IhERG by 90% has
been suggested to be relatively little affected by mutation at F656
[12]. These observations raise the possibility that binding determi-
nants of amiodarone inhibition of hERG channels may be qualita-
tively or quantitatively different from those for canonical high
affinity hERG inhibitors. The present study was undertaken to elu-
cidate the nature of the interaction between amiodarone and the
hERG channel, through mutagenesis of amino acids from the S6
and pore-helix regions that line the channel’s inner cavity together
with in silico docking and molecular dynamics simulations. The
results obtained show that, whilst in common with other drugs
amiodarone binds within the hERG channel inner cavity, the roles
of S6 aromatic residues are quantitatively smaller than for high
affinity selective IKr/IhERG inhibitors [20,21] and that other residues
contribute significantly to amiodarone’s blocking action.
2. Materials and methods
2.1. Mutagenesis
An alanine-scanning approach was used to examine most of the
individual residues from the S6 helix and the H5 pore/selectivity
filter for possible interaction with amiodarone. The residues exam-
ined with the alanine scan are highlighted in Fig. 3A. Alanine was
chosen because of its small size and its likely ability to minimise
interruptions in secondary structure in tightly packed regions of
the channel and this approach is an established one for studying
structural determinants of hERG channel blockade [20,21,23].
Alanine mutants of hERG at the base of the pore helices near the
selectivity filter (T623A, S624A, V625A) and the S6 helix (L646A,
I647A, G648A, S649A, M651A, S654A, G657A, N658A, V659A,
S660A, I663A, Q664A, R665A, L666A and Y667A) were constructed
using the QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA) as previously reported ([24–26], see Table 1 for pri-
mers used). L622A, L650A, I655A, and I662A are excluded from this
list as they do not express channels that conduct currents [20,23].
A pair of complementary oligonucleotide primers (forward primers
and reverse primers were synthesised by Sigma-Genosys, Haver-
hill, UK, see Table 1) were used in a PCR (95 C for 1 min, 60 C
for 1 min, 68 C for 16 min for 18 cycles) using hERG in a modified
pcDNA3.0 vector as a DNA template. A DpnI (New England Biolabs
Ltd, Herts, UK) digest of the PCR mix was then performed for 1 h at
37 C. Competent DH5a Escherichia coli (Invitrogen, Paisley, UK)
were transformed using standard procedures. Mutations were con-
firmed by sequencing the entire open reading frame (Eurofins
MWG Operon, Ebersberg, Germany).
2.2. Maintenance of mammalian cell lines and cell transfection
Experiments on wild-type hERG were performed on a cell line
(Human Embryonic Kidney; HEK 293) stably expressing hERG
(generously donated by Dr. Craig January, University of Wisconsin).
HEK 293 cell lines stably expressing mutant F656A and Y652A
hERG were created in our laboratory using standard techniques:
appropriately mutated hERG sequences were subcloned into a
hERG expression vector (based on pIRES1hyg) into the BstEII/
Sse8387I sites of hERG; the expression constructs were transfected
Table 1
Mutagenic primers for alanine mutants in S6 helix of hERG.
Mutant Primer sequence (50–30)
L646A Forward: CATCTGCGTCATGGCCATTGGCTCCCTC
Reverse: GAGGGAGCCAATGGCCATGACGCAGATG
I647A Forward: CATCTGCGTCATGCTCGCTGGCTCCCTCATGTATG
Reverse: CATACATGAGGGAGCCAGCGAGCATGACGCAGATG
G648A Forward: CGTCATGCTCATTGCCTCCCTCATGTATG
Reverse: CATACATGAGGGAGGCAATGAGCATGACG
S649A Forward: GTCATGCTCATTGGCGCCCTCATGTATGC
Reverse: GCATACATGAGGGCGCCAATGAGCATGAC
M651A Forward: GCTCATTGGCTCCCTCGCGTATGCTAGCATCTTCG
Reverse: CGAAGATGCTAGCATACGCGAGGGAGCCAATGAGC
S654A Forward: CTCATGTATGCTGCCATCTTCGG
Reverse: CCGAAGATGGCAGCATACATGAG
G657A Forward: GCTAGCATCTTCGCCAACGTGTCGG
Reverse: CCGACACGTTGGCGAAGATGCTAGC
N658A Forward: GCTAGCATCTTCGGCGCAGTGTCGGCCATCATC
Reverse: GATGATGGCCGACACTGCGCCGAAGATGCTAGC
V659A Forward: CATCTTCGGCAACGCGTCGGCCATCATCC
Reverse: GGATGATGGCCGACGCGTTGCCGAAGATG
S660A Forward: CTTCGGCAACGTGGCGGCCATCATCC
Reverse: GGATGATGGCCGCCACGTTGCCGAAG
I663A: Forward: GTCGGCCATCGCCCAGCGGCTG
Reverse: CAGCCGCTGGGCGATGGCCGAC
Q664A Forward: GTCGGCCATCATCGCGCGGCTGTACTCG
Reverse: CGAGTACAGCCGCGCGATGATGGCCGAC
R665A Forward: CCATCATCCAGGCGCTGTACTCGG
Reverse: CCGAGTACAGCGCCTGGATGATGG
L666A Forward: CCATCATCCAGCGGGCGTACTCGGGCACAG
Reverse: CTGTGCCCGAGTACGCCCGCTGGATGATGG
Y667A Forward: CATCCAGCGGCTGGCCTCGGGCACAGCC
Reverse: GGCTGTGCCCGAGGCCAGCCGCTGGATG
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using Fugene (Roche Diagnostics, West Sussex, UK) into HEK 293
cells, selected, subcloned, and assayed for hERG expression by
immunofluorescence (using Alomone APC-016, Jerusalem, Israel)
followed by electrophysiological validation [27]. Cells were pas-
saged using enzyme free cell dissociation solution (Millipore, Wat-
ford, UK) and plated onto sterilised 13-mm glass coverslips in 40-
mm petri dishes containing a modification of Dulbecco minimum
essential medium with Glutamax-1 (DMEM; Invitrogen, Paisley,
UK). This was supplemented with 10% fetal bovine serum, 50 lg/
mL gentamycin (Invitrogen, Paisley, UK), and 400 lg/mL geneticin
(G418, Invitrogen, Paisley, UK) for WT or 100 lg/mL of hygromycin
for Y652A and F656A [14,24–27]. For other mutants, HEK293 cells
(ECACC, Porton Down, UK) were transiently transfected with cDNA
plasmids using Lipofectamine 2000 (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions. Expression plasmid
encoding CD8 was also added (in pIRES, donated by Dr. I Baró,
University of Nantes, France) as a marker for successful transfec-
tion. Recordings were performed 12–72 h after transfection. Suc-
cessfully transfected cells (positive to CD8) were identified using
Dynabeads (Invitrogen, Paisley, UK) [24–26].
2.3. Solutions, electrophysiological recordings, experimental protocol
and data analysis
Once in the recording chamber, cells were superfused with nor-
mal Tyrode’s solution containing (in mM): 140 NaCl, 4 KCl, 2.5
CaCl2, 1 MgCl2, 10 Glucose, and 5 HEPES (titrated to pH of 7.45 with
NaOH). For experiments with mutants T623A, G648A, F656A and
the corresponding WT control, the superfusate contained 94 mM
KCl (with NaCl concentration correspondingly reduced) [25,26].
Patch-pipettes (Corning 7052 glass, AM Systems, Carlsborg, USA)
were pulled and heat-polished (Narishige MF83, Tokyo, Japan) to
2.5–4 MX; pipette dialysate contained (in mM): 130 KCl, 1 MgCl2,
5 EGTA, 5 MgATP, 10 HEPES (titrated to pH 7.2 using KOH) [14,24–
26]. Amiodarone (Sigma–Aldrich, Gillingham, UK) was dissolved in
dimethyl sulfoxide to produce a stock solution of 50 mM, which
was serially diluted to produce stock solutions ranging from
50 mM to 5 lM. The amiodarone stock solutions were then diluted
1:1000-fold with Tyrode solution to achieve concentrations stated
in Section 3.
Measurements of hERG current (IhERG) were made at 37 ± 1 C as
described previously [14,24–27]. It has already been established
that some of the mutant channels do not conduct adequate current
using a traditional hERG protocol (depolarisation to +20 mV, fol-
lowed by repolarisation to 40 mV), due to changes in the chan-
nel’s activation/inactivation kinetics, ion selectivity/sensitivity or
expression level [20,21,28]. The selection of external [K+] and
voltage-protocol for each mutant was informed by prior studies
and experience. Activating voltage commands to +20 mV were
used, with tail currents observed at either 40 mV (for most
mutants), or 120 mV (T623A, V625A, G648A, F656A, V659A)
[20,21,25,26,29,30]. High external [K+] conditions were used for
comparatively poorly expressing mutations (T623A, G648A, and
F656A) [25,26,30]. For all mutants studied, block levels were
attained by repetitive stimulation for 10 min and fractional inhibi-
tion of IhERG tails measured. The data for each mutant were com-
pared with WT IhERG studied under comparable conditions; in all
cases tail current measurements were evaluated (outward tail at
40 mV or inward tail at 120 mV with normal (4 mM) or raised
(94 mM) [K+]) as in previous studies [25–27,30].
Data were shown as mean ± SEM of the number of independent
experiments indicated (n). Statistical comparisons were made
using a Student t test or a one-way analysis of variance (ANOVA)
followed by a Bonferroni post-test, as appropriate. p values <0.05
were considered statistically significant.
2.4. Concentration–response data and correction for IhERG run-down
The fractional block (FB) of IhERG ‘‘tails” by the different drug
concentrations studied was determined using the equation:
Fractional block ¼ 1 ððIhERG-AMIODÞ=IhERG-CONTROLÞ ð1Þ
where ‘‘Fractional block” refers to the degree of inhibition of hERG
current by a given concentration of amiodarone. IhERG-AMIOD and
IhERG-CONTROL represent ‘‘tail” current amplitudes in the presence
and absence of amiodarone.
Concentration–response data were fitted by a standard Hill
equation of the form:
Fractional block ¼ 1=ð1þ ðIC50=½AMIODÞhÞ ð2Þ
where IC50 is [AMIOD] producing half-maximal inhibition of the
IhERG tail and h is the Hill coefficient for the fit.
As observed previously for amiodarone and its relatives [12,14],
amiodarone exhibited a progressive development of IhERG blockade,
reaching a stable level of block by 10 min of drug exposure, with
continuous application throughout this period of the voltage proto-
col shown in Fig. 1A (start-to-start interval of 12 s). During this
period, there was some overlying rundown of IhERG. Therefore,
control experiments were performed to correct concentration–
response data for IhERG rundown. To do this, WT IhERG was moni-
tored during a 2–3 min stabilisation period followed by a 10-min
recording period in normal Tyrode’s solution. The mean level of
rundown of IhERG tails following pulses to +20 mV during this
10 min period was 12.8% ± 1.8% of the peak outward tail magni-
tude (n = 5 cells). We subtracted 12.8% of current magnitude from
the last tail current in the control periods and used the resulting
value to calculate fractional block following (10 min) exposure to
amiodarone. All concentration response data were run-down cor-
rected, except for V659A, for which a clear pattern of run-down
was absent. The correction procedure used for concentration
response relations is in accord with that adopted previously for
the study of amiodarone and its major metabolite desethylamio-
darone [14].
2.5. Computational docking and molecular dynamics simulations
In the absence of a crystal structure for the hERG channel pore,
computational docking of amiodarone to hERG was conducted
using a homology model encompassing the pore helix, selectivity
filter and S6 helix, built onto the crystal structure template of
the MthK structure (pdb: 1LNQ) [31]. This model is described else-
where [25,32]. We recently showed that this model accords well
with experimental data on drug block for a range of structurally-
diverse hERG blockers [32]. Computational docking was conducted
as described in [32] using the FlexiDock module of Sybyl (Certara,
St. Louis, MO, USA) which allows unrestricted sampling of side
chain bond rotations. Free side chain flexibility was sampled for
the following residues: T623, S624, V625, Y652, F656 and S660.
Definition of the drug-binding pocket, construction of starting con-
figurations and choice of genetic algorithm parameters were car-
ried out as described previously [25,32]. A version of our hERG
pore model including the S5 transmembrane helix (Dempsey
et al., unpublished) was used for performing molecular dynamics
simulations in a fully-hydrated bilayer membrane model to test
the stability of amiodarone in its low energy score docked state
and to explore amiodarone block of K+ diffusion and binding within
the pore. Molecular dynamics simulations were done in a palmi
toyl-oleoyl-phosphatidylcholine (POPC) bilayer membrane patch
with 15 Å layers of water containing K+ and Na+ ions equivalent
to a concentration of 140 mM above and below the membrane in
a periodic boundary system with Gromacs [33] using methods
26 Y. Zhang et al. / Biochemical Pharmacology 113 (2016) 24–35
described previously [34]. Structural figures and movies were
made using Pymol [35] and VMD [36] respectively.
3. Results
3.1. IhERG inhibition by amiodarone
The sensitivity of IhERG to amiodarone was determined using the
voltage protocol shown in Fig. 1A (continuously applied with a
start-to-start interval of 12 s) [14,25,26]. Tail current magnitude
at 40 mV was measured relative to instantaneous current
observed during a brief (50 ms) depolarisation to 40 mV that pre-
ceded the +20 mV step depolarisation [14,25,26]. Fig. 1A shows
representative traces in Control and in the presence of 100 nM
amiodarone (AMIOD), which resulted in 70% inhibition of the
IhERG tail. The interaction of some drugs with hERG is influenced
by the direction of K+ flux [12,25,26]. The effect of reversal of the
direction of K+ ion flux on potency of amiodarone action was deter-
mined using the protocol shown in Fig. 1B (a 2 s depolarising step
to +20 mV followed by a 500-ms hyperpolarising step to
120 mV), measuring inward IhERG tails at 120 mV. As shown in
the inset to Fig. 1B the extent of inward IhERG tail inhibition by
100 nM amiodarone was less extensive than that seen for the out-
ward tail current in Fig. 1A. A range of amiodarone concentrations
was tested, for both outward and inward IhERG tail inhibition, with
concentration–response relations shown in Fig. 1C. The sensitivity
to amiodarone of inward IhERG in the presence of raised [K+]e was
also examined (this was necessitated by the requirement to have
WT data under similar conditions as required to study some ala-
nine mutants). The IC50 and h values derived from the fits to the
data (Fig. 1C) were: outward tail 45.0 ± 5.2 nM, 1.0 ± 0.1; inward
tail 93.3 ± 12.8 nM, 0.8 ± 0.1; inward tail with raised [K+]e
117.8 ± 31.0 nM, 0.8 ± 0.2.
Sensitivity of WT IhERG to amiodarone under ventricular action
potential (AP) clamp was also determined (Fig. 1D; with the AP
command applied at a start-to-start interval of 3 s). Maximal IhERG
during AP repolarisation was inhibited 65.5 ± 4.3% (n = 7) by
100 nM AMIOD, compared with 66.5 ± 7.0% (n = 5) with the stan-
dard protocol shown in Fig. 1A (p > 0.05, t test). The voltage at
which peak IhERG during repolarisation occurred was
20.6 ± 2.7 mV in control and 23.3 ± 2.4 mV in amiodarone
(p > 0.05, t test).
3.2. The time-dependence of inhibition on IhERG by amiodarone
A prior study, conducted utilising Xenopus oocyte expression,
has suggested that hERG channel inhibition by amiodarone exhi-
bits both gated-state and closed-state components [10]. However,
we previously found that the closed-channel block component for
IhERG recorded from mammalian cells at physiological temperature
was likely to be small for the amiodarone relative dronedarone
[12]. We therefore investigated the issue of gated versus non-
gated block for amiodarone using a similar approach to that previ-
ously adopted in studying dronedarone [12].
Fig. 1. Effect of amiodarone on WT IhERG. (A, B) Representative current traces show outward (A) or inward WT IhERG tail (B) in control (normal 4 mM [K+]e Tyrode’s) solution
and after 10 min application of 100 nM amiodarone (AMIOD), the current was evoked by the protocol shown in the lower panel and is shown on an expanded time-scale
(denoted by the boxed area) in (B). Tail currents recorded at 40 mV or 120 mV were used to assess amiodarone inhibition. (C) Concentration response curves for outward
and inward WT IhERG tail inhibition by amiodarone in normal 4 mM [K+]e and 94 mM [K+]e Tyrode’s (high [K+]e). Data were fitted with a Hill-equation (nP 5 cells per data-
point). For IC50 and h values refer to Section 3, also see [14]. (D) Representative current traces in control (normal 4 mM [K+]e Tyrode’s) solution and in 100nM amiodarone,
overlying the applied AP voltage command.
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During a sustained depolarisation (a 10 s step to 0 mV from a
holding potential of 80 mV), IhERG block showed progressive
development with increased time during depolarisation, indicative
of time-dependence of inhibition (data not shown), although this
approach does not discriminate well between gated/non-gated
inhibition over short time-periods. In order to investigate time-
dependence of IhERG inhibition over comparatively short time peri-
ods immediately following membrane depolarisation, the paired
pulse protocol shown in Fig. 2A was used. This was applied from
a holding potential of 100 mV, which greatly favours the closed
channel state(s), and was comprised of two depolarising com-
mands to +40 mV: the first of short duration (5 or 10 ms) and the
second of longer duration (500 ms). The IhERG tail at 40 mV after
each command was measured. The protocol was applied under
control conditions, was discontinued whilst the cells were exposed
to 600 nM amiodarone for 3 min, and was then reapplied in the
maintained presence of drug. As the channels were not gated
through open/inactive states during the resting period during drug
exposure, any block seen after the first brief (5 ms or 10 ms) depo-
larisation would be expected to result either from closed channel
block or from very rapidly developing gated channel block. The
channels were gated for longer during the 500 ms depolarisation.
Representative traces are shown in Fig. 2B. We found the current
traces in control and after amiodarone following 5 ms or 10 ms
steps to +40 mV showed negligible difference (p > 0.05), but were
substantially smaller in amiodarone following the 500 ms step.
The bar chart in Fig. 2C displays the mean fractional block of IhERG
tails following 5 ms (n = 7), 10 ms (n = 6), and 500 ms (n = 13) steps
to +40 mV. For 5 ms pulses tail current was inhibited by 3.4 ± 1.7%
(n = 7); inhibition was 8.3 ± 8.1% for the 10 ms pulse (p > 0.05 com-
pared with 5 ms pulse), with a marked increase to 48.6 ± 7.3% for
the 500 ms pulse (p < 0.001 compared with both 5 ms and
10 ms). It is important to note that the protocol was applied only
once in the presence of drug and so the mean values here do not
represent steady-state block. However, the results from this exper-
iment indicate clearly that IhERG block by amiodarone is very lar-
gely gated-state dependent and that any component of closed
channel block with the drug is likely to be small.
3.3. Alanine-scanning of potential amiodarone binding residues
Key drug binding residues on the hERG channel reside in the S6
and pore helices of the channel [20,21,37]. We therefore conducted
an alanine scan of pore helix and S6 residues (shown in Fig. 3A).
Initial experiments utilised an amiodarone concentration at
600 nM; at steady state it produced 94.5 ± 0.0% block of WT
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Fig. 2. The time-dependence of inhibition of IhERG by amiodarone. (A) Is a schematic representation of paired pulse voltage protocol used to elicit currents shown in (B) (Bi)
shows representative current traces elicited during and following both 5 ms and 500 ms (n = 7) or (Bii) both 10 ms and 500 ms (n = 6, right) steps to +40 mV, in the absence
and presence of 600 nM amiodarone (applied for 3 min in the absence of pulsing). (C) The bar chart displays the mean fractional block of IhERG tails following the different
duration steps to +40 mV. **p < 0.001 compared to 500 ms step, one way ANOVA followed by Bonferroni’s post test (5 ms, n = 7; 10 ms, n = 6; 500 ms, n = 13).
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outward tail current (Fig. 3Bi); 82.6 ± 0.0% block of inward tail cur-
rent in normal [K+]e and 75.8 ± 0.02% block of inward tail current in
94 mM high [K+]e (Fig. 3Bi, Bii, and Biii, p < 0.001 compared with
WT outward tail current). As shown in Fig. 3B (for S660A, V625A
and T623A) inhibition of individual alanine mutants was compared
to inhibition of WT IhERG under similar recording conditions. The
mean normalised remaining currents at steady state following
drug application were calculated and plotted in Fig. 3C (IAMIOD/
IControl), with larger values indicating smaller fractional block. As
shown in Fig. 3C, IhERG inhibition for each of the S6 domain mutants
G648A, Y652A, F656A and V659A was statistically significantly dif-
ferent from the corresponding WT control. Three mutant channels
located in the base of the pore helix (T623A, S624A, V625A) were
also significantly less sensitive to amiodarone. To characterise fur-
ther the relative importance of specific residues to the drug bind-
ing sites, we determined concentration–response relations for the
6 mutant channels least affected by drug.
3.4. Concentration-dependent IhERG inhibition of the S6 domain
mutations by amiodarone
Fig. 4A shows the effects of 1 lM amiodarone on Y652A hERG.
This concentration, expected to produce well over 90% inhibition
of WT IhERG tails (see the concentration–response relation for
Fig. 3. Alanine-scanning mutagenesis of hERG to define binding sites for amiodarone. (A) Sequence alignment for hERG and the MthK channel, highlighting the pore helix and
S6 transmembrane domains. The residues of hERG analysed in this study by Ala-scanning mutagenesis are underlined. Bottom pair highlight amino acid identities (-), strong
similarities (:). Amino acids in red text have side chains facing the pore cavity of the MthK structure. Note that the last four residues of S6 in the MthK structure italicised
(INRE) are not seen in the crystal structure and aren’t included in the hERG model. (B) Example traces showing IhERG inhibition of WT or mutants in transient transfected
HEK293 cells, IhERG was recorded before (control) and after achieving steady-state block of current with 600 nM amiodarone. Voltage protocols are shown in each lower panel.
(C) Normalised current (IAMIOD/Icontrol) measured after steady-state block by 600nM amiodarone (n = 5–6 for each point; error bars, ±SEM). A value of 1 indicates no current
inhibition by amiodarone (**p < 0.001 compared to its WT, one way ANOVA followed by Bonferroni’s post test).
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outward IhERG tails in Fig. 1C), produced 50% block of Y652A IhERG
(upper traces); the lower panel of Fig. 4A shows the mean concen-
tration–response relations for Y652A IhERG and for its WT control.
The derived IC50 and h values for Y652A-hERG were
912.8 ± 61.3 nM and 1.1 ± 0.1, thus the IC50 was 20-fold its WT
control. Fig. 4B (upper traces) shows representative traces for
F656A IhERG and its WT control; the lower panel shows correspond-
ing concentration response relations. The derived IC50 and h values
for F656A hERG were 2121.6 ± 168.6 nM and 1.4 ± 0.1: 17-fold its
WT control. Fig. 4C and D show similar data for G648A hERG (IC50
and h of 673.9 ± 2.2 nM and 1.9 ± 0.0: 5.7-fold its WT control) and
V659A hERG respectively (IC50 and h of 921.9 ± 498 nM, 0.9 ± 0.4:
9.9-fold its WT control).
3.5. Concentration-dependent IhERG inhibition of the pore helix
mutations by amiodarone
T623A and S624A hERG were also studied but V625A was not
included in full concentration–response studies. This is because,
although the alanine scan identified V625 to influence amiodarone
block, under our conditions it was found to be technically difficult
to maintain sufficiently sustained recordings from V625A IhERG to
obtain full concentration–response data for amiodarone. Fig. 5A
shows data for T623A hERG. 1 lM amiodarone blocked inward
IhERG by 68.8 ± 6.1%, with concentration response data yielding
IC50 and h values of 765.5 ± 287.8 nM and 0.9 ± 0.4. S624A hERG
can be studied under similar conditions to WT at normal [K+]e
Fig. 4. Effect of S6 mutations on amiodarone inhibition of IhERG. Representative traces from Y652A (A), F656A (B), G648A (C) and V659A (D) before (Control) and after
achieving steady-state block by amiodarone, with the voltage protocol underneath. Lower panel shows concentration–response relation for the mutant (black) and its
corresponding WT control (grey), yielding the IC50 and h values in section 3. (For all, nP 5 cells per data-point). Note that for some data-points in (A), (B), (C) the SEM values
are small and obscured by the symbols.
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and Fig. 5B shows representative traces for the effect of 1 lM amio-
darone and the corresponding concentration–response relation,
yielding IC50 and h values of 979.2 ± 84.3 nM and 1.1 ± 0.1. The
IC50 for T623A hERG was 6.5-fold its WT control and for S624A
hERG was 21.7-fold its WT control. Table 2 summarises experi-
mental data from all the mutants for which full concentration–re-
sponse relations were obtained.
3.6. Docking of amiodarone into a hERG pore homology model
Docking of amiodarone into the MthK-based homology model
of the hERG pore resulted in drug-bound states that are broadly
consistent with the experimental data (Fig. 6). The predominant
conformational state from docking using FlexiDock was one in
which the drug was oriented with the tertiary aliphatic amino
group near the top of the channel pore cavity, in or near the inter-
nal binding site for a K+ ion [31,38] and the bulky iodinated aro-
matic group lower down in the cavity; a representative structure
is shown in Fig. 6. In this state the drug makes multiple interac-
tions with the aromatic side chains of Y652 and F656, consistent
with the reduction in drug block in hERG Y652A and F656A (Figs. 3
and 4). The location of the protonated tertiary aliphatic amino
group near the internal K+ binding site is consistent with the effect
of inward K+ flux in reducing amiodarone block potency (Fig. 1C) as
a result of direct competition of drug and K+ for binding in the pore
cavity. The location of amiodarone high in the pore cavity with the
protonated tertiary amino group located just below the selectivity
filter near S624 is also consistent with the reduction in amiodarone
block in hERG S624A (Figs. 3C and 5). These interpretations are
supported by molecular dynamics simulations of amiodarone in
the low energy score docked conformation within a membrane-
embedded MthK model extended to include the S5 helix (Movies
1 and 2). In the absence of drug, K+ ions were observed to diffuse
into the pore cavity through the open gate on the cytoplasmic side
of the channel and periodically to occupy the internal K+ binding
site (Movie 1). The bound configuration of amiodarone within
the channel pore was found to be stable (Movie 2) and in this loca-
tion the drug blocked K+ ions from interacting with the internal K+
binding site, and indeed entirely blocked K+ ions from entering the
pore cavity.
4. Discussion
4.1. Clinical relevance
Previous experiments using Xenopus oocytes yielded an amio-
darone IC50 value for IhERG of 9.8 lM [10] whilst in mammalian
expression systems IhERG IC50 values between 26 and 300 nM
were reported [12–14,16,17]. Amiodarone is highly lipophilic and
for such agents the use of Xenopus oocytes can markedly underes-
timate blocking potency due to drug accumulation in the yolk sac
[39,40]. Amiodarone has also been shown to produce greater IhERG
block at physiological (37 C) than at ambient (23 C) temperature
(IC50 of 0.30 lM versus 0.56 lM, respectively) [17]. Our IC50 of
45 nM is consistent with the potency of inhibition observed pre-
viously [12–14,16,17]. The comparable levels of WT IhERG inhibition
observed here with conventional and AP voltage clamp (Fig. 1) is
predictive of significant inhibition of IKr during physiological wave-
forms within the plasma clinical concentration range (1.6–5.9 lM)
[41]. Prior data from Xenopus oocyte experiments suggest that, at a
Fig. 5. Effect of pore helix mutations on amiodarone inhibition of IhERG. Representative traces from T623A (A) and S624A (B) before (Control) and after achieving steady-state
block by amiodarone, with the voltage protocol underneath. Lower panel shows concentration–response relation for the mutant (black) and its corresponding WT control
(grey), yielding the IC50 and h values in Section 3. (For all, nP 5 cells per data-point.) Note that for some data-points the SEM values are small and obscured by the symbols.
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holding potential of 80 mV, recovery of IhERG from block between
successive commands in the presence of drug would be anticipated
to be small at cycle lengths of 10 s or less [42]. Our data are con-
sistent with this, as the AP and step protocols used in Fig. 1
achieved similar levels of block despite differences not only in
waveform type, but also in protocol application frequency. Thus,
little recovery of IhERG from block would be anticipated at
physiological heart rates. Recently, results have been reported that
some ion channel effects of amiodarone that underlie the drug’s
clinical actions may result from physical effects of the drug on
the lipid bilayer in which ion channels reside [43]. The struc-
ture–functional analysis in the present study indicates that IhERG
channel inhibition (and consequently the associated Class III effect
of the drug) results from a direct channel-drug interaction within
the channel pore and not from a physical effect of the drug on
the lipid bilayer.
4.2. Mechanism of WT IhERG block
Amiodarone has been reported to block hERG channels
expressed in Xenopus oocytes in closed, open, and inactivated
states [10]. Whilst the electrophysiological discrimination between
closed and rapid open state channel block can be challenging
[27,44], the use of protocols similar to that shown in Fig. 2A can
provide some clarification in discriminating gated (open/inacti-
vated) from closed state inhibition [12]. Thus, we observed negligi-
ble block of IhERG tails when these were elicited by 5 or 10 ms brief
commands in the presence of amiodarone. Additionally, with the
protocol employed in Fig. 2, currents in the absence and presence
of amiodarone elicited by 500 ms commands initially overlaid
one another and then diverged as IhERG block developed during
the depolarisation (Fig. 2Bi, Bii). It is likely, therefore, that any
closed channel block component, if present, is slight. Prior studies
Table 2
Effect of pore helix and S6 mutations on IhERG inhibition by amiodarone.
Channel Voltage step
(mV)
K+
(mM)
Tested amiod concentration range
(n numbers per concentration)
(nM)
IC50 (mean ± SEM)
(nM)
h Shift in potency
compared to its
WT-control
Shift in WT potency
compared to WT-1
WT-1 40 4 3–600
(5–6)
45.0 ± 5.2 1.0 ± 0.1
WT-2 120 4 10–600
(5)
93.3 ± 12.8 0.8 ± 0.1 2.1
WT-3 120 94 10–1000
(5)
117.8 ± 31.0 0.8 ± 0.2 2.6
T623A 120 94 100–10,000
(5–6)
765.5 ± 287.8 0.9 ± 0.4 6.5
S624A 40 4 100–10,000
(5–6)
979.2 ± 84.3 1.1 ± 0.1 21.8
G648A 120 94 100–10,000
(4–6)
673.9 ± 2.2 1.9 ± 0.0 5.7
Y652A 40 4 100–10,000
(5–6)
912.8 ± 61.3 1.1 ± 0.1 20.3
F656A 120 94 10–10,000
(5–8)
2021.6 ± 168.6 1.4 ± 0.1 17.2
V659A 120 4 100–10,000
(5)
921.9 ± 498.0 0.9 ± 0.4 9.9
Fig. 6. Representative low energy score docking output for amiodarone in the MthK-based hERG pore homology model. (A) Amiodarone is shown in relation to the amino acid
residues described in the text: blue: F656, pink: Y652; green: T623, S624, V625. These residues are also annotated in (B) which highlights the set of interactions between
amiodarone and specific amino acid side chains including two pi-stacking interactions between F656 and amiodarone aromatic rings, and two cation–pi interactions and one
hydrogen bond involving the protonated amino group and Y656 side chains. The location of the aliphatic amino group near the internal binding site for a K+ ion is indicated by
the blue star. Stabilisation of the protonated amino group in this location may be enhanced by the hydroxyl side chain groups of S624. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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have demonstrated that amiodarone inhibition of IhERG shows a
moderate dependence on inactivation that is intermediate
between that of Class I antiarrhythmic drugs (low) and other Class
III methansulphonanilides (high) [13,22]. Titration of the level of
IhERG inactivation through the use of single and double mutations
that impair inactivation resulted in graded changes to amiodarone
IC50: the N588 K and S631A mutations each resulted in IC50 values
4-fold that for WT IhERG, whilst the N588 K/S631A double mutation
resulted in an IC50 value 29-fold that of WT IhERG [13]. Thus, when
the data from the present study are considered alongside results of
prior studies [10,13,22], gated state block is likely to involve inter-
actions with both activated and inactivated channels. Although
IhERG inactivation is reduced in high [K+]e [45], the reduced sensi-
tivity (increased IC50) for IhERG block by amiodarone for inward
IhERG tail current with both normal as well as raised [K+]e suggests
that the effect of reversing the direction of K+ flux on blocking
potency is likely to result from a direct interaction between K+ ions
and amiodarone, rather than a consequence of altered inactivation
[25]. Moreover, a direct interaction involving electrostatic repul-
sion or ‘‘knock-off” [45,46] is consistent with amiodarone binding
within the K+ ion conduction pathway, supported by the results
of our docking analysis (Fig. 6) and MD simulations (Movies 1
and 2).
4.3. Molecular determinants of block
The apparently large size of the central cavity below the selec-
tivity filter, and the positioning of the aromatic side chains of Y652
and F656 on S6 allow hERG to accommodate diverse drugs [18,20].
Although we have previously identified a partial dependence of
amiodarone block on aromatic residues within the hERG channel
cavity [12], to our knowledge, the present study is the first to make
an extensive and quantitative description of the side chains in the
hERG channel cavity that constitute determinants of amiodarone
block. This study locates the binding site of the drug within the
K+ permeation pathway below the selectivity filter. Mutation to
alanine of T623, S624, V625 located near or within the selectivity
filter, and G648, Y652, F656, V659 in the S6 helix, all attenuated
amiodarone block (Fig. 3C). These mutations are similar to those
attenuating block by the methanesulphonanilides E-4031, MK-
499, dofetilide and ibutilide [20,21,23,47], but differ somewhat
from those for terfenadine and cisapride, for which high affinity
block was little affected in V625A and G648A mutants [48].
Although the binding residues for gated-state hERG inhibitors gen-
erally involve combinations of those investigated here, it has been
noted previously that the relative importance of particular residues
can vary between compounds [21,48]. The results of the present
study agree with this notion, though direct quantitative compar-
isons with previous analyses of the molecular determinants of IhERG
block by other drugs is limited by the fact that alanine scanning of
the hERG pore cavity has often utilised only a single (profound-
blocking) concentration [12,21,23,48] and/or not all the residues
studied here have been investigated [49]. Full IC50 determination
for drug block of a range of hERG alanine mutants has been
described for MK-499, terfenadine, cisapride [20], clofilium and
ibutilide [50] in Xenopus oocytes at room temperature.
Perhaps the most significant feature of amiodarone binding
compared to other high affinity blockers (see Table 3) is the smaller
effect of alanine replacement of either of Y652 and F656 (17–20-
fold increases in IC50 for block) than has been seen previously for
high affinity methanesulphonanilides. For example, Lees-Miller
et al. reported the IC50 for dofetilide block of hERG F656V to be
120-fold that of WT [47], whilst Mitcheson et al. reported values
of 650-fold and 94-fold WT respectively, for F656A and Y652A
mutations [20]. Subsequent work identified substantial attenua-
tion of IhERG block by both dofetilide and E-4031 with Y652A and
F656A mutations at single (high) drug concentrations [21]. IC50
values for IhERG block by cisapride and terfenadine were also
substantially elevated by Y652A and F656A mutations [20,51]. A
striking feature of our results is the similar effect of pore-helix/
selectivity filter mutations and S6 aromatic mutations on amio-
darone inhibition of IhERG. Thus, the relative importance for amio-
darone binding (based on measured IC50 values, so excluding
V625A) of the residues studied here is: S624A  Y652A >
F656A > V659A > G648A > T623A. This compares with F656
Y652 > G648 = V625 > T623 > S624 = V659 for MK-499 [20].
4.4. Computational docking and molecular dynamics simulations
Comparison of residues that make defined interactions with
amiodarone in docked states (Fig. 6) with those having reduced
amiodarone block in the alanine scan (Fig. 3; Table 2), identifies
side chains for which the effects of alanine replacement are likely
to result from direct interaction with the drug. The patch of molec-
ular surface defined by residues affecting amiodarone sensitivity in
the alanine scan (Fig. 7B) is considerably larger than the molecular
Table 3
Comparison of IC50 fold change to WT in pore helix and S6 mutants for some high affinity hERG inhibitors.
Agents Cell line Recording temperature WT IC50 (nM) IC50 fold increase (mutant IC50/WT IC50) Ref.
Pore helix S6
T623A S624A V625A G648A Y652A F656A V659A
Amiodarone HEK293 37 C 45 6.5 22 6 (E) 5.7 20 17 9.9 This paper
Clomipramine HEK293 36 C 130 [56]
Oocyte Room temperature 12,400 6 12
Cisapride Oocyte Room temperature 133 2 1 100 40 [20]
Clofilium Oocyte Room temperature 30 12 381 250 1329 484 [23,50]
Dofetilide estimated Oocyte Room temperature 420 7 9 130 171 25 62 3 [21]
E-4031 estimated Oocyte Room temperature 570 4 13 86 40 31 89 4 [21]
Ibutilide Oocyte Room temperature 28 54 93 >300 140 (E) 67 (E) 140 (E) 18 (E) [23]
MK-499 Oocyte Room temperature 34 5 54 55 94 650 [20]
Terfenadine Oocyte Room temperature 134 1.5 1.5 150 100 [20]
Verapamil HEK293 Room temperature 143 [57,58]
Oocyte 5100 16 20
Ziprasidone HEK293 37 C 120 [59]
Oocyte Room temperature 2800 140 357
E: estimated. This table shows the effects of mutations in the pore-helix/selectivity filter region (T623A, S624A, V652A) and S6 helix (G648, Y652A, F656A, V659A) on IhERG
block by some high affinity hERG inhibitors, the fold change in IC50 relative to its corresponding WT control is given as IC50 mutant/IC50 WT. Where ‘‘estimated” fold change
values are given, experimentally derived IC50 values were not given and so the estimated values used here were calculated using single dose data available in the relevant
paper, by using a standard Hill equation (Eq. (2)): fractional block = 1/(1 + (IC50/[drug])h), and assuming h = 1.
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surface of amiodarone (Fig. 7A) and these residues cannot all
simultaneously interact with drug. Direct interaction between
amiodarone and S624, Y652 and F656 likely accounts for the
marked attenuation of amiodarone block in S624A, Y652A and
F656A, respectively. The effects of V625A, G648A and V659A are
likely to result from indirect (allosteric) effects on amiodarone
binding. The reduction in sensitivity of V625A to amiodarone
may result from conformational perturbation around the selectiv-
ity filter, which disrupts ion selectivity and inactivation, and/or
repositioning of S624 so that it is not optimally oriented for
high-affinity binding [50,52]. Whilst the V659A mutation reduces
the potency of many compounds [53], this side chain is likely to
be oriented away from the pore cavity, assuming that the S6 helix
retains a helical conformation through this sequence (Fig. 7B). This
indicates that this residue is unlikely to be a direct binding deter-
minant. Indeed, the V659A mutation significantly alters gating,
shifting the voltage dependence of activation by 30 mV and
reduces drug block potency by increasing rates of recovery from
block between pulses [53]. These effects may be mediated via
interactions with the S5 helix. The reduction in amiodarone block
of G648A hERG is similar to the effect of this mutation on high
affinity blockers such as dofetilide, ibutilide and MK-499 but not
cisapride [53]. Larger residues in this position may alter the posi-
tioning of other inner cavity residues [53,54], so the reduction in
amiodarone sensitivity may be due to an allosteric effect of this
mutation. The potential for indirect (allosteric) effects of mutations
on drug binding highlights the value of considering the results of
mutagenesis experiments alongside structural and docking infor-
mation, as provided by Figs. 6 and 7 and molecular dynamics
Movies 1 and 2 in this study.
The low energy score conformation of amiodarone with the ali-
phatic amino group near the cavity K+ binding site just below S624
(Fig. 6) is stable during MD simulations within the membrane-
embedded pore model (Movie 2). This orientation of amiodarone
is consistent with the effects on drug block of a series of amio-
darone analogues with modified substituents around the amino
group that produced marked changes in IC50 values for hERG block
[55]. A positively charged amino group is required for high block-
ing efficacy [55] and this likely reflects a location of this group
beneath the selectivity filter where interactions with S624 and
Y652 side chains, and the cavity K+ binding site are possible. Thus,
high affinity block of IhERG by amiodarone is favoured by drug bind-
ing high in the pore cavity within the K+ ion conduction pathway
and interacting with S624 as strongly as with Y652.
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